MedTrace Logo

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

NCT07745361 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-08-04

No results posted yet for this study

Summary

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer.

Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.

Conditions

Interventions

DRUG

Oral MRT-2359

Orally administered tablets of MRT-2359

DRUG

Apalutamide

Orally administered apalutamide

Sponsors & Collaborators

  • Monte Rosa Therapeutics, Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-10-31
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07745361 on ClinicalTrials.gov